Complementary DNAs

a technology of complementary dnas and dnas, applied in the field of complementary dnas, can solve the problems of requiring years of effort, affecting the purification effect of desired proteins, and even a single human gene characterization process was a painstaking process, so as to facilitate the purification of desired proteins

Inactive Publication Date: 2007-01-11
SERONO GENETICS INST SA
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0028] The present invention also relates to secretion vectors capable of directing the secretion of a protein of interest. Such vectors may be used in gene therapy strategies in which it is desired to produce a gene product in one cell which is to be delivered to another location in the body. Secretion vectors may also facilitate the purification of desired proteins.

Problems solved by technology

In the past, the characterization of even a single human gene was a painstaking process, requiring years of effort.
However, this approach entails sequencing large stretches of human DNA which do not encode proteins in order to find the protein encoding sequences scattered throughout the genome.
In addition to requiring extensive sequencing, the bio-informatics software may mischaracterize the genomic sequences obtained.
Thus, the software may produce false positives in which non-coding DNA is mischaracterized as coding DNA or false negatives in which coding DNA is mislabeled as non-coding DNA.
In part, the prevalence of EST sequences derived from the 3′ end of the mRNA is a result of the fact that typical techniques for obtaining cDNAs, are not well suited for isolating cDNA sequences derived from the 5′ ends of mRNAs.
Furthermore, they may not include some exons, often short ones, which are located upstream of splicing sites.
Public information on the number of human genes for which the promoters and upstream regulatory regions have been identified and characterized is quite limited.
In part, this may be due to the difficulty of isolating such regulatory sequences.
Upstream regulatory sequences such as transcription factor binding sites are typically too short to be utilized as probes for isolating promoters from human genomic libraries.
Both of these approaches have their limits due to a lack of specificity or of comprehensiveness.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Complementary DNAs
  • Complementary DNAs
  • Complementary DNAs

Examples

Experimental program
Comparison scheme
Effect test

example 1

Ligation of the Nucleoside Diphosphate pCp to the 3′ End of Messenger RNA

[0077] 1 μg of RNA was incubated in a final reaction medium of 10 μl in the presence of 5 U of T4 phage RNA ligase in the buffer provided by the manufacturer (Gibco-BRL), 40 U of the RNase inhibitor RNASIN (Promega) and, 2 μl of 32 pCp (Amersham #PB 10208).

[0078] The incubation was performed at 37° C. for 2 hours or overnight at 7-8° C.

[0079] Following modification or elimination of the 2′,3′-cis diol at the 3′ ribose, the 2′,3′-cis diol present at the 5′ end of the mRNA may be oxidized using reagents such as NaBH4, NaBH3CN, or sodium periodate, thereby converting the 2′,3′-cis diol to a dialdehyde. Example 2 describes the oxidation of the 2′,3′-cis diol at the 5′ end of the mRNA with sodium periodate.

example 2

Oxidation of 2′,3′-cis Diol at the 5′ End of the mRNA

[0080] 0.1 OD unit of either a capped oligoribonucleotide of 47 nucleotides (including the cap) or an uncapped oligoribonucleotide of 46 nucleotides were treated as follows. The oligoribonucleotides were produced by in vitro transcription using the transcription kit AMPLISCRIBE T7 (Epicentre Technologies). As indicated below, the DNA template for the RNA transcript contained a single cytosine. To synthesize the uncapped RNA, all four NTPs were included in the in vitro transcription reaction. To obtain the capped RNA, GTP was replaced by an analogue of the cap, m7G(5′)ppp(5′)G. This compound, recognized by polymerase, was incorporated into the 5′ end of the nascent transcript during the step of initiation of transcription but was not capable of incorporation during the extension step. Consequently, the resulting RNA contained a cap at its 5′ end. The sequences of the oligoribonucleotides produced by the in vitro transcription reac...

example 3

Coupling of the Dialdehyde with Biotin

[0083] The oxidation product obtained in Example 2 was dissolved in 50 μl of sodium acetate at a pH of between 5 and 5.2 and 50 μl of freshly prepared 0.02 M solution of biotin hydrazide in a methoxyethanol / water mixture (1:1) of formula:

[0084] In the compound used in these experiments, n=5. However, it will be appreciated that other commercially available hydrazides may also be used, such as molecules of the formula above in which n varies from 0 to 5.

[0085] The mixture was then incubated for 2 hours at 37° C. Following the incubation, the mixture was precipitated with ethanol and dialyzed against distilled water.

[0086] Example 4 demonstrates the specificity of the biotinylation reaction.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The sequences of extended cDNAs encoding secreted proteins are disclosed. The extended cDNAs can be used to express secreted proteins or portions thereof or to obtain antibodies capable of specifically binding to the secreted proteins. The extended cDNAs may also be used in diagnostic, forensic, gene therapy, and chromosome mapping procedures. The extended cDNAs may also be used to design expression vectors and secretion vectors.

Description

RELATED APPLICATIONS [0001] The present application is a divisional of U.S. patent application Ser. No. 10 / 930,331, filed Aug. 30, 2004, which is a divisional application of U.S. patent application Ser. No. 09 / 903,190, filed Jul. 11, 2001, now U.S. Pat. No. 6,936,692, which is a divisional application of U.S. patent application Ser. No. 09 / 247,155, filed Feb. 9, 1999, now U.S. Pat. No. 6,312,922, which claims the benefit of U.S. Provisional Patent application Ser. No. 60 / 074,121, filed Feb. 9, 1998, U.S. Provisional Patent application Ser. No. 60 / 081,563, filed Apr. 13, 1998, U.S. Provisional Patent application Ser. No. 60 / 096,116, filed Aug. 10, 1998, and U.S. Provisional Patent application Ser. No. 60 / 099,273, filed Sep. 4, 1998, the disclosures of which are incorporated herein by reference in their entirety. [0002] Table I lists the SEQ ID Nos. of the extended cDNAs in the present application, the SEQ ID Nos. of the extended cDNAs in the provisional applications, and the identiti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & AuthorityApplications(United States)
IPC IPC(8): C12Q1/68C07H21/04C12P21/06C07K14/705C12N15/09A61K48/00C07K14/47C07K16/18C12M1/00C12N1/15C12N1/19C12N1/21C12N5/10C12N15/12C12P21/02G06F17/30
CPCA61K48/00C07K14/705C07K14/47Y02A90/10
InventorDUMAS MILNE EDWARDS, JEAN-BAPTISTEDUCLERT, AYMERICBOUGUELERET, LYDIE
OwnerSERONO GENETICS INST SA